Oleksandr Baturevych

Title: Oleksandr Baturevych: Innovator in Immunotherapy

Introduction

Oleksandr Baturevych is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of immunotherapy, particularly through his innovative approaches to therapeutic T cells.

Latest Patents

Baturevych holds a patent titled "Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors." This patent involves methods, compositions, and uses that relate to immunotherapies and inhibitors of target protein tyrosine kinases. The patent specifically addresses kinases that are not IL-2-inducible T cell kinase (ITK) and includes Bruton's tyrosine kinase (BTK), tec protein tyrosine kinase (TEC), BMX non-receptor tyrosine kinase (Etk), TXK tyrosine kinase (TXK), and receptor tyrosine-protein kinase ErbB4 (ErbB4). The methods and compositions provided in this patent aim to enhance the activity, efficacy, persistence, expansion, and proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents.

Career Highlights

Throughout his career, Oleksandr Baturevych has worked with prominent companies in the biotechnology sector. He has been associated with Juno Therapeutics, Inc. and Acerta Pharma B.V., where he has contributed to advancing therapeutic strategies in immunology.

Collaborations

Baturevych has collaborated with notable professionals in his field, including Michael Ports and Jim Qin. These collaborations have further enriched his work and contributions to immunotherapy.

Conclusion

Oleksandr Baturevych is a distinguished inventor whose work in immunotherapy has the potential to significantly impact the treatment of various diseases. His innovative approaches and collaborations continue to drive advancements in the field.